A prospective, randomised, controlled, multi-centre comparative effectiveness study of healing using dehydrated human amnion/chorion membrane allograft, bioengineered skin substitute or standard of care for treatment of chronic lower extremity diabetic ulcers

Charles M Zelen, Lisa Gould, Thomas E Serena, Marissa J Carter, Jennifer Keller, William W Li, Charles M Zelen, Lisa Gould, Thomas E Serena, Marissa J Carter, Jennifer Keller, William W Li

Abstract

A prospective, randomised, controlled, parallel group, multi-centre clinical trial was conducted at three sites to compare the healing effectiveness of treatment of chronic lower extremity diabetic ulcers with either weekly applications of Apligraf(®) (Organogenesis, Inc., Canton, MA), EpiFix(®) (MiMedx Group, Inc., Marietta, GA), or standard wound care with collagen-alginate dressing. The primary study outcome was the percent change in complete wound healing after 4 and 6 weeks of treatment. Secondary outcomes included percent change in wound area per week, velocity of wound closure and a calculation of the amount and cost of Apligraf or EpiFix used. A total of 65 subjects entered the 2-week run-in period and 60 were randomised (20 per group). The proportion of patients in the EpiFix group achieving complete wound closure within 4 and 6 weeks was 85% and 95%, significantly higher (all adjusted P-values ≤ 0·003) than for patients receiving Apligraf (35% and 45%), or standard care (30% and 35%). After 1 week, wounds treated with EpiFix had reduced in area by 83·5% compared with 53·1% for wounds treated with Apligraf. Median time to healing was significantly faster (all adjusted P-values ≤0·001) with EpiFix (13 days) compared to Apligraf (49 days) or standard care (49 days). The mean number of grafts used and the graft cost per patient were lower in the EpiFix group campared to the Apligraf group, at 2·15 grafts at a cost of $1669 versus 6·2 grafts at a cost of $9216, respectively. The results of this study demonstrate the clinical and resource utilisation superiority of EpiFix compared to Apligraf or standard of care, for the treatment of diabetic ulcers of the lower extremities.

Keywords: Advanced wound care; Amniotic membrane; Comparative effectiveness; Cost effectiveness; Diabetic ulcers.

© 2014 The Authors. International Wound Journal published by Medicalhelplines.com Inc and John Wiley & Sons Ltd.

Figures

Figure 1
Figure 1
Rates of complete healing at 4 and 6 weeks for each study group.
Figure 2
Figure 2
Mean percent healing overall and per patient per week.
Figure 3
Figure 3
The Kaplan–Meier analysis of the time to healing by study group.

References

    1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:4–14; doi: 10.1016/j.diabres.2009.10.007.
    1. American Diabetes Association . Economic costs of diabetes in the U.S. in 2012. Diabetes Care 2013;36:1033–46.
    1. Boulton AJ, Armstrong DG, Albert SF, Frykberg RG, Hellman R, Kirkman MS, Lavery LA, Lemaster JW, Mills JL Sr, Mueller MJ, Sheehan P, Wukich DK, American Diabetes Association , American Association of Clinical Endocrinologists . Comprehensive foot examination and risk assessment: a report of the task force of the foot care interest group of the ADA, with endorsement by the AACE. Diabetes Care 2008;8:1679–85.
    1. Driver VR, de Leon JM. Health economic implications for wound care and limb preservation. J Manag Care Med 2008;11:13–9.
    1. Snyder R. Wound percent area reduction and making decisions about utilizing advanced therapies. Podiatry Manage 2010;29:197–201.
    1. Steed DL, Attinger C, Colaizzi T, Crossland M, Franz M, Harkless L, Johnson A, Moosa H, Robson M, Serena T, Sheehan P, Veves A, Wiersma‐Bryant L. Guidelines for the treatment of diabetic ulcers. Wound Repair Regen 2006;14:680–92.
    1. Albert S. Cost‐effective management of recalcitrant diabetic foot ulcers. Clin Podiatr Med Surg 2002;19:483–91.
    1. Ho C, Tran K, Hux M, Sibbald G, Campbell K. Artificial skin grafts in chronic wound care: a meta‐analysis of clinical efficacy and a review of cost‐effectiveness [Tech. Rep. No. 52]. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 2005.
    1. Veves A, Falanga V, Armstrong DG, Sabolinski ML. Apligraf diabetic foot ulcer study. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care 2001;24:290–5.
    1. Marston WA, Hanft J, Norwood P, Pollak R, Dermagraft Diabetic Foot Ulcer Study Group . The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care 2003;26:1701–5.
    1. Zelen CM, Serena TE, Denoziere G, Fetterolf DE. A prospective randomized comparative parallel study of amniotic membrane wound graft in the management of diabetic foot ulcers. Int Wound J 2013;10:502–7.
    1. Fetterolf DE, Istwan NB, Stanziano GJ. An evaluation of healing metrics associated with commonly used advanced wound care products for the treatment of chronic diabetic foot ulcers. Manag Care 2014;23:31–8.
    1. FDA (US Food and Drug Administration) . Apligraf, labeling, approval order, summary of safety and effectiveness. PMA # P950032, Docket # 00M‐1508; 2000. Sep 11. URL [accessed on 4 September 2014]
    1. Koob TJ, Rennert R, Zabek N, Massee M, Lim JJ, Temenoff JS, Li WW, Gurtner G. Biological properties of dehydrated human amnion/chorion composite graft: implications for chronic wound healing. Int Wound J 2013;10:493–500.
    1. Maan ZN, Rennert RC, Koob TJ, Januszyk M, Li WW, Gurtner GC. Cell recruitment by amnion chorion grafts promotes neovascularization. J Surg Res 2014; pii: S0022‐4804(14)00803‐8; doi: 10.1016/j.jss.2014.08.045.
    1. Zelen CM. An evaluation of dehydrated human amniotic membrane allografts in patients with DFUs. J Wound Care 2013;22:347–8 350–51.
    1. Zelen CM, Serena TE, Snyder RJ. A prospective, randomised comparative study of weekly versus biweekly application of dehydrated human amnion/chorion membrane allograft in the management of diabetic foot ulcers. Int Wound J 2014;11:122–8.
    1. Centers for Medicare and Medicaid Services . Medicare Part B drug average sales price, July 2014 ASP drug pricing files 09/03/14. URL [accessed on 24 September 2014]
    1. Shores JT, Gabriel A, Gupta S. Skin substitutes and alternatives: a review. Adv Skin Wound Care 2007;20:493–508, quiz 509–10.
    1. Schultz GS, Davidson JM, Kirsner RS, Bornstein P, Herman IM. Dynamic reciprocity in the wound microenvironment. Wound Repair Regen 2011;19:134–48.
    1. Li WW, Talcott KE, Zhai AW, Kruger EA, Li VW. The role of therapeutic angiogenesis in tissue repair and regeneration. Adv Skin Wound Care 2005;18:491–500.
    1. Wojtowicz AM, Oliveira S, Carlson MW, Zawadzka A, Rousseau CF, Baksh D. The importance of both fibroblasts and keratinocytes in a bilayered living cellular construct used in wound healing. Wound Repair Regen 2014;22:246–55; doi: 10.1111/wrr.12154.
    1. Brem H, Young J, Tomic‐Canic M, Isaacs C, Ehrlich HP. Clinical efficacy and mechanism of bilayered living human skin equivalent (HSE) in treatment of diabetic foot ulcers. Surg Technol Int 2003;11:23–31.
    1. Osborne CS, Schmid P. Epidermal‐dermal interactions regulate gelatinase activity in Apligraf, a tissue‐engineered human skin equivalent. Br J Dermatol 2002;146:26–31.
    1. John T. Human amniotic membrane transplantation: past, present, and future. Ophthalmol Clin North Am 2003;16:43–65.
    1. Niknejad H, Peirovi H, Jorjani M, Ahmadiani A, Ghanavi J, Seifalian AM. Properties of the amniotic membrane for potential use in tissue engineering. Eur Cell Mater 2008;15:88–99.
    1. Koob TJ, Lim JJ, Massee M, Zabek N, Denozière G. Properties of dehydrated human amnion/chorion composite grafts: implications for wound repair and soft tissue regeneration. J Biomed Mater Res B Appl Biomater 2014;102:1353–62; doi: 10.1002/jbm.b.33141.
    1. Chen Z, Wang Y, Shi C. Therapeutic implications of newly identified stem cell populations from the skin dermis. Cell Transplant 2014,[Epub ahead of print].
    1. Kokai LE, Marra K, Rubin JP. Adipose stem cells: biology and clinical applications for tissue repair and regeneration. Transl Res 2014;163:399–408; doi: 10.1016/j.trsl.2013.11.009.
    1. Gallagher KA, Liu ZJ, Xiao M, Chen H, Goldstein LJ, Buerk DG, Nedeau A, Thom SR, Velazquez OC. Diabetic impairments in NO‐mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF‐1 alpha. J Clin Invest 2007;117:1249–59.
    1. Badillo AT, Chung S, Zhang L, Zoltick P, Liechty KW. Lentiviral gene transfer of SDF‐1alpha to wounds improves diabetic wound healing. J Surg Res 2007;143:35–42.
    1. Koob TJ, Lim JJ, Zabek N, Massee M. Cytokines in single layer amnion allografts compared to multi‐layered amnion/chorion allografts for wound healing. J Biomed Mater Res B Appl Biomater 2014; doi: 10.1002/jbm.b.33265 [Epub ahead of print].
    1. Langer A, Rogowski W. Systematic review of economic evaluations of human cell‐derived wound care products for the treatment of venous leg and diabetic foot ulcers. BMC Health Serv Res 2009;9:115; doi: 10.1186/1472-6963-9-115.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi